An exciting study in NEJM has found that the combination of the drugs, ibrutinib and venetoclax, improves outcomes for chronic lymphocytic leukemia (CLL) compared to standard chemo-immunotherapy. The therapy, guided by measurable residual disease (MRD), led to a notable improvement in progression-free survival and reduced the risk of infection. Furthermore, 58% of patients stopped therapy due to undetectable MRD after three years, which may transform treatments for CLL, the most common type of leukemia in adults. #india #technology #innovation https://lnkd.in/d2DcdjhD
Groundbreaking research published in NEJM demonstrates that combining ibrutinib and venetoclax significantly improves outcomes for chronic lymphocytic leukemia patients versus chemo-immunotherapy. Using measurable residual disease to guide therapy delivery led to enhanced progression-free survival and decreased infection risk. Remarkably, 58% of patients were able to stop treatment after 3 years due to undetectable MRD, representing a potential therapeutic breakthrough. This novel targeted regimen could transform the standard-of-care for CLL, the most prevalent adult leukemia. With improved efficacy and tolerability over chemo, ibrutinib plus venetoclax guided by MRD monitoring may soon emerge as a new gold standard for tackling this hematologic malignancy.
Positive data that represent very encouraging developments for patients. Perhaps a few pricing and reimbursement specialists may be considering early retirement!
Very exciting for the impending day where all these cancers where there was spread and it was claimed intervention to have noclinical benefit get revisited
Coordenador de Laboratório | Citogenética | Genética Médica | Produção
7mo👍🏻great